H R Rosen

Summary

Country: USA

Publications

  1. ncbi Early hepatitis C viral kinetics correlate with long-term outcome in patients receiving high dose induction followed by combination interferon and ribavirin therapy
    Hugo R Rosen
    Division of Gastroenterology and Hepatology, Portland Veterans Affairs Medical Center, Portland, OR 97207, USA
    J Hepatol 37:124-30. 2002
  2. ncbi Curricular guidelines for training in transplant hepatology
    Hugo R Rosen
    Liver and Intra-Abdominal Subcommittee, American Society for Transplantation, USA
    Liver Transpl 8:85-7. 2002
  3. ncbi A longitudinal analysis of T-cell epitope-coding regions of hepatitis C virus after liver transplantation
    Hugo R Rosen
    Department of Medicine, and Divisions of Gastroenterology Hepatology and Liver Transplantation, and Infectious Diseases, Portland Veterans Affairs Medical Center, Portland, Oregon 97207, USA
    Transplantation 74:209-16. 2002
  4. ncbi Hepatitis B and C in the liver transplant recipient: current understanding and treatment
    H R Rosen
    Division of Gastroenterology Hepatology and Liver Transplantation Program, Portland Veterans Administration and Oregon Health Sciences University, Portland, OR 97207, USA
    Liver Transpl 7:S87-98. 2001
  5. ncbi Hepatitis C in the liver transplant recipient: current understanding and treatment
    Hugo R Rosen
    Division of Gastroenterology Hepatology and Liver Transplantation Program, Oregon Health and Sciences University, PO Box 1034, P3 GI, 3710 SW US Veterans Hospital Rd, Portland, OR 97207, USA
    Microbes Infect 4:1253-8. 2002
  6. ncbi Hepatitis C virus in the human liver transplantation model
    Hugo R Rosen
    Department of Medicine, Liver Transplantation Program, Oregon Health and Science University, 3181 Sam Jackson Park Road, Portland, OR 97207, USA
    Clin Liver Dis 7:107-25. 2003
  7. ncbi Disease recurrence following liver transplantation
    H R Rosen
    Division of Gastroenterology Hepatology, Liver Transplantation Program, Portland Veterans Affairs, Oregon Health Sciences University, Portland, Oregon, USA
    Clin Liver Dis 4:675-89, ix-x. 2000
  8. ncbi Hepatitis B and C in the liver transplant recipient
    H R Rosen
    Division of Gastroenterology Hepatology and Liver Transplantation Program, Portland Veterans Administration, and Oregon Health Sciences University, P O Box 1034, 111 A, 3710 SW U S Veterans Hospital Rd, Portland, OR 97207, USA
    Semin Liver Dis 20:465-80. 2000
  9. ncbi Retransplantation for hepatitis C: implications of different policies
    H R Rosen
    Division of Gastroenterology Hepatology and Liver Transplantation Program, Portland Veterans Affairs Medical Center Oregon Health Sciences University, Portland, OR 97207, USA
    Liver Transpl 6:S41-6. 2000
  10. ncbi Viral hepatitis in the liver transplant recipient
    H R Rosen
    Research Development for Gastrointestinal Hepatology Fellowship Program, Oregon Health Sciences University, USA
    Infect Dis Clin North Am 14:761-84. 2000

Collaborators

Detail Information

Publications66

  1. ncbi Early hepatitis C viral kinetics correlate with long-term outcome in patients receiving high dose induction followed by combination interferon and ribavirin therapy
    Hugo R Rosen
    Division of Gastroenterology and Hepatology, Portland Veterans Affairs Medical Center, Portland, OR 97207, USA
    J Hepatol 37:124-30. 2002
    ..The majority of patients with genotype 1 do not respond to interferon (IFN) plus ribavirin. Limited data exist on the use of induction followed by combination therapy...
  2. ncbi Curricular guidelines for training in transplant hepatology
    Hugo R Rosen
    Liver and Intra-Abdominal Subcommittee, American Society for Transplantation, USA
    Liver Transpl 8:85-7. 2002
  3. ncbi A longitudinal analysis of T-cell epitope-coding regions of hepatitis C virus after liver transplantation
    Hugo R Rosen
    Department of Medicine, and Divisions of Gastroenterology Hepatology and Liver Transplantation, and Infectious Diseases, Portland Veterans Affairs Medical Center, Portland, Oregon 97207, USA
    Transplantation 74:209-16. 2002
    ..We hypothesized that amino acid substitutions within critical T-cell epitopes could lead to increased severity of HCV disease...
  4. ncbi Hepatitis B and C in the liver transplant recipient: current understanding and treatment
    H R Rosen
    Division of Gastroenterology Hepatology and Liver Transplantation Program, Portland Veterans Administration and Oregon Health Sciences University, Portland, OR 97207, USA
    Liver Transpl 7:S87-98. 2001
    ..5. HCV-related allograft cirrhosis is associated with a high rate of decompensation and mortality...
  5. ncbi Hepatitis C in the liver transplant recipient: current understanding and treatment
    Hugo R Rosen
    Division of Gastroenterology Hepatology and Liver Transplantation Program, Oregon Health and Sciences University, PO Box 1034, P3 GI, 3710 SW US Veterans Hospital Rd, Portland, OR 97207, USA
    Microbes Infect 4:1253-8. 2002
    ..Identification of patients who are likely to develop progressive HCV-related allograft injury is important to optimize results of current antiviral therapy...
  6. ncbi Hepatitis C virus in the human liver transplantation model
    Hugo R Rosen
    Department of Medicine, Liver Transplantation Program, Oregon Health and Science University, 3181 Sam Jackson Park Road, Portland, OR 97207, USA
    Clin Liver Dis 7:107-25. 2003
    ....
  7. ncbi Disease recurrence following liver transplantation
    H R Rosen
    Division of Gastroenterology Hepatology, Liver Transplantation Program, Portland Veterans Affairs, Oregon Health Sciences University, Portland, Oregon, USA
    Clin Liver Dis 4:675-89, ix-x. 2000
    ..As a varying proportion of the first generation of liver transplant patients develop severe recurrence and graft failure, policies of organ allocation for retransplantation will be challenged...
  8. ncbi Hepatitis B and C in the liver transplant recipient
    H R Rosen
    Division of Gastroenterology Hepatology and Liver Transplantation Program, Portland Veterans Administration, and Oregon Health Sciences University, P O Box 1034, 111 A, 3710 SW U S Veterans Hospital Rd, Portland, OR 97207, USA
    Semin Liver Dis 20:465-80. 2000
    ..Optimal antiviral strategies for hepatitis C post-OLT have yet to be identified...
  9. ncbi Retransplantation for hepatitis C: implications of different policies
    H R Rosen
    Division of Gastroenterology Hepatology and Liver Transplantation Program, Portland Veterans Affairs Medical Center Oregon Health Sciences University, Portland, OR 97207, USA
    Liver Transpl 6:S41-6. 2000
    ..5. Retransplantation is the only viable option for patients in whom allografts fail because of recurrent HCV disease...
  10. ncbi Viral hepatitis in the liver transplant recipient
    H R Rosen
    Research Development for Gastrointestinal Hepatology Fellowship Program, Oregon Health Sciences University, USA
    Infect Dis Clin North Am 14:761-84. 2000
    ..However, effective prophylactic regimens that alter the natural history of HCV reinfection do not currently exist, and with longer follow-up into the second decade, the prevalence of HCV-related graft failure is likely to increase...
  11. ncbi Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation
    H R Rosen
    Department of Medicine, Portland Veterans Affairs Medical Center Oregon Health Sciences University, Portland, Oregon
    Gastroenterology 117:926-32. 1999
    ..The purpose of this analysis was to determine the correlation between HCV-specific peripheral CD4(+) T-cell responses and the severity of recurrence after liver transplantation...
  12. ncbi Hepatitis C virus: current understanding and prospects for future therapies
    H R Rosen
    Division of Gastroenterology and Hepatology, Portland VA Medical Center, Portland, OR 97207, USA
    Mol Med Today 5:393-9. 1999
    ..The main hindrance to drug development for hepatitis C is the lack of a small animal model or a productive tissue culture system for assessing drug action...
  13. ncbi Validation and refinement of survival models for liver retransplantation
    Hugo R Rosen
    Division of Gastroenterology Hepatology, Portland VAMC and Oregon Health and Science University, Portland, OR 97207, USA
    Hepatology 38:460-9. 2003
    ..In conclusion, prospective validation and use of these models as adjuncts to clinical decision making in the management of patients being considered for re-OLT are warranted...
  14. ncbi Late mortality after orthotopic liver transplantation
    J M Rabkin
    Department of Surgery, Division of Abdominal Organ Transplantation, Oregon Health Sciences University and Portland Veterans Affairs Medical Center, 3181 SW Sam Jackson Park Road, L590, Portland, OR 97201 3098, USA
    Am J Surg 181:475-9. 2001
    ..The aim of this study was to determine the incidence of late mortality and to identify the most common causes and risk factors associated with late mortality after OLTx...
  15. ncbi Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin
    D V Gopal
    Divisions of Gastroenterology and Hepatology, Oregon Health Sciences Center and Portland Veteran Affairs Medical Center, 37 SW US Veterans Hospital Rd, Portland, OR 97201, USA
    Liver Transpl 7:181-90. 2001
    ..Multicenter trials using combination therapy to identify factors predictive of response are needed in the subset of patients with progressive allograft injury...
  16. ncbi Review article: the treatment of hepatitis C virus recurrence after liver transplantation
    R R Arjal
    Division of Gastroenterology and Hepatology, University of Colorado at Denver and Health Sciences Center, Denver, CO 80262, USA
    Aliment Pharmacol Ther 26:127-40. 2007
    ..Given the potentially significant impact that hepatitis C recurrence has on graft and patient survival, several treatment strategies have been utilized to prevent/slow the progression to hepatitis C-related graft failure...
  17. ncbi Association of cytomegalovirus genotype with graft rejection after liver transplantation
    H R Rosen
    Department of Medicine, Portland Veterans Affairs Medical Center and Oregon Health Sciences University, 97207, USA
    Transplantation 66:1627-31. 1998
    ..Our aim was to define the distribution of CMV gB genotypes and the impact on acute cellular rejection and graft/patient survival after orthotopic liver transplantation (OLT)...
  18. ncbi A model to predict survival following liver retransplantation
    H R Rosen
    Division of Gastroenterology Hepatology, Portland Veterans Affairs Oregon Health Sciences University, OR, USA
    Hepatology 29:365-70. 1999
    ..We have developed and validated a model that uses five readily accessible "bedside" variables to accurately predict survival in patients undergoing liver retransplantation...
  19. ncbi T-cell clones derived by CD3 stimulation from hepatitis C virus explanted liver tissue are not representative of dominant clones present in vivo
    M P Davey
    Department of Veterans Affairs Medical Center, Oregon Health Sciences University, 3710 SW U S Veterans Hospital Rd, Bldg 101, Rm 502, Portland, OR 97201, USA
    Liver Transpl 7:716-23. 2001
    ....
  20. ncbi Tacrolimus is associated with a lower incidence of cardiovascular complications in liver transplant recipients
    J M Rabkin
    Department of Surgery, Division of Abdominal Organ Transplantation, Oregon Health Sciences University and Portland Veterans Affairs Medical Center, 3181 SW Sam Jackson Park Road, L590, Portland, OR 97201-3098, USA
    Transplant Proc 34:1557-8. 2002
  21. ncbi Impaired plasmacytoid dendritic cell maturation and differential chemotaxis in chronic hepatitis C virus: associations with antiviral treatment outcomes
    J A Mengshol
    Division of Gastroenterology and Hepatology, Department of Medicine, University of Colorado Denver, Colorado, USA
    Gut 58:964-73. 2009
    ..Studies to date have produced inconsistent results regarding DC maturation and function: no large study has examined DCs before and after therapy...
  22. ncbi Treatment of HCV recurrence: do the pretransplantation rules apply?
    James R Burton
    Liver Transpl 12:1044-8. 2006
  23. ncbi Natural killer cells: primary target for hepatitis C virus immune evasion strategies?
    Lucy Golden-Mason
    University of Colorado Health Sciences Center, Denver, CO
    Liver Transpl 12:363-72. 2006
    ....
  24. ncbi Differential antigenic hierarchy associated with spontaneous recovery from hepatitis C virus infection: implications for vaccine design
    Susan Smyk-Pearson
    Division of Gastroenterology and Hepatology, Hepatitis C Center, and Integrated Program in Immunology, University of Colorado Health Sciences Center and National Jewish Hospital, Denver, 80262, USA
    J Infect Dis 194:454-63. 2006
    ....
  25. ncbi Diagnosis and management of allograft failure
    James R Burton
    Division of Gastroenterology and Hepatology, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, B154, Denver, CO 80262, USA
    Clin Liver Dis 10:407-35, x. 2006
    ..It also discusses the complex problems involved in retransplantation for allograft failure...
  26. ncbi Liver retransplantation for hepatitis C virus recurrence: a survey of liver transplant programs in the United States
    James R Burton
    Division of Gastroenterology Hepatology, Oregon Health and Science University and Portland Veterans Administration Medical Center, Portland, Oregon 97239, USA
    Clin Gastroenterol Hepatol 3:700-4. 2005
    ..To gain insight into how transplant centers are dealing with this issue and whether published prognostic factors are being used, we conducted a survey of liver transplant centers across the US in late 2003...
  27. ncbi Reconstitution of hepatitis C virus-specific T-cellmediated immunity after liver transplantation
    Scott J Weston
    Department of Medicine, Oregon Health and Science University, USA
    Hepatology 41:72-81. 2005
    ..Supplementary material for this article can be found on the HEPATOLOGY website (http://interscience. wiley.com/jpages/0270-9139/suppmat/index.html)...
  28. ncbi Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence
    Lucy Golden-Mason
    Division of Gastroenterology and Hepatology, Hepatitis C Center, and Integrated Program in Immunology, University of Colorado Health Sciences Center and National Jewish Hospital, Denver, CO, USA
    Hepatology 44:1098-109. 2006
    ..These data provide a mechanistic basis for the observation that CTLs generated in early infection rapidly decline as chronicity is established; CD127 expression should be considered in the design of novel immunotherapeutic approaches...
  29. ncbi Phenotypic and functional changes of cytotoxic CD56pos natural T cells determine outcome of acute hepatitis C virus infection
    Lucy Golden Mason
    Division of Gastroenterology and Hepatology, Hepatitis C Center, University of Colorado at Denver Health Sciences Center, and National Jewish Hospital, Denver, Colorado, USA
    J Virol 81:9292-8. 2007
    ..These results indicate a previously unappreciated role for NT cells in acute HCV infection and identify a potential target for pharmacologic manipulation...
  30. ncbi Cutting edge: programmed death-1 expression is increased on immunocytes in chronic hepatitis C virus and predicts failure of response to antiviral therapy: race-dependent differences
    Lucy Golden-Mason
    Division of Gastroenterology and Hepatology, Hepatitis C Center, University of Colorado Health Sciences Center and National Jewish Hospital, Aurora, CO 80045, USA
    J Immunol 180:3637-41. 2008
    ..Collectively, these data indicate that PD-1 is critical in persistent HCV and successful therapy results in global down-regulation of its expression...
  31. ncbi Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy
    Hugo R Rosen
    Integrated Program in Immunology and Hepatitis C Research Center, Division of Gastroenterology and Hepatology, University of Colorado, Denver, CO, USA
    Hepatology 46:350-8. 2007
    ..CONCLUSION: Compared to CAs, AAs have weaker HCV-specific immunity. Pretreatment HCV-specific immunity is associated with response to combination antiviral therapy...
  32. ncbi Liver retransplantation for hepatitis C: seeing is believing
    Hugo R Rosen
    Liver Transpl 13:1217-8. 2007
  33. ncbi Acute rejection in HCV-infected liver transplant recipients: The great conundrum
    James R Burton
    Division of Gastroenterology and Hepatology, Liver Transplantation Program and Hepatitis C Research Center, University of Colorado at Denver and Health Sciences Center, Denver, CO 80262, USA
    Liver Transpl 12:S38-47. 2006
    ..6. Mild rejection per se is not associated with graft loss and treatment of rejection with steroids and OKT3 is associated with worse outcome in HCV; thus, it seems logical that we should no longer treat mild rejection...
  34. ncbi Transplantation immunology: what the clinician needs to know for immunotherapy
    Hugo R Rosen
    Division of Gastroenterology and Hepatology, Liver Transplantation, Hepatitis C Center, Department of Medicine, University of Colorado Health Sciences Center, Aurora, Colorado 80045, USA
    Gastroenterology 134:1789-801. 2008
    ....
  35. ncbi Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance
    Chia C Wang
    Department of Medicine, Division of Infectious Diseases, University of Washington, 325 Ninth Avenue, Seattle, WA 98104, USA
    J Infect Dis 196:1474-82. 2007
    ..Acute hepatitis C virus (HCV) infection is often asymptomatic; thus, its epidemiology and natural history are difficult to define...
  36. ncbi Functional suppression by FoxP3+CD4+CD25(high) regulatory T cells during acute hepatitis C virus infection
    Susan Smyk-Pearson
    Division of Gastroenterology and Hepatology, Hepatitis C Center, University of Colorado Health Sciences Center, GI Division, 4200 E 9th Ave, B 158, Denver, CO 80262, USA
    J Infect Dis 197:46-57. 2008
    ....
  37. ncbi Retransplantation for hepatitis C: what do we really know?
    James R Burton
    Liver Transpl 10:1504-6. 2004
  38. ncbi Cutting edge: identification of hepatitis C virus-specific CD8+ T cells restricted by donor HLA alleles following liver transplantation
    Hugo R Rosen
    Hepatology and Liver Transplantation Program, Portland Veterans Affairs Medical Center Oregon Health and Sciences University, Portland, OR 97207, USA
    J Immunol 173:5355-9. 2004
    ..The in vitro specificity to donor HLA allele-restricted CD8+ T cells suggests that these cells may function to control HCV spread in the allograft...
  39. ncbi Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: correlation with clinical disease stages
    Hugo R Rosen
    Department of Medicine, Portland Veterans Affairs Medical Center/Oregon Health and Science University, Portland OR 97207, USA
    Hepatology 35:190-8. 2002
    ..Prospective studies using this new flow cytometric assay will be required to determine whether antiviral therapy modifies the frequency, specificity, and function of these virus-specific effector cells...
  40. ncbi Tumor necrosis factor-alpha promoter polymorphisms and the risk of rejection after liver transplantation: a case control analysis of 210 donor-recipient pairs
    Saad F Jazrawi
    Liver Transplantation Program, the Division of Gastroenterology Hepatology, Portland Veterans Administration Medical Center, OR 97207, USA
    Liver Transpl 9:377-82. 2003
    ..In this large case control analysis of patients undergoing liver transplantation for diverse etiologies, TNF promoter polymorphisms were not independently associated with rejection or survival...
  41. ncbi Duration of antiviral therapy for cholestatic HCV recurrence may need to be indefinite
    Deepak V Gopal
    Division of Gastroenterology, Oregon Health and Sciences Center, Portland, USA
    Liver Transpl 9:348-53. 2003
    ..Thus, based on our experience, we recommend that duration of antiviral therapy in the subset of patients with cholestatic HCV recurrence should be indefinite...
  42. ncbi Graft failure from severe recurrent primary sclerosing cholangitis following orthotopic liver transplantation
    Deepak V Gopal
    Division of Gastroenterology and Hepatology, Oregon Health Sciences University and Portland VA Medical Center, Portland, Oregon 97207, USA
    J Clin Gastroenterol 37:344-7. 2003
    ..CONCLUSIONS: Although most series report mild recurrence of PSC following OLT, this case illustrates that early, severe recurrence of PSC may occur, leading to graft failure and need for re-transplantation...
  43. ncbi Hepatitis C pathogenesis: mechanisms of viral clearance and liver injury
    Hugo R Rosen
    Division of Gastroenterology Hepatology, Portland Veterans Affairs Medical Center, Portland, OR 97207, USA
    Liver Transpl 9:S35-43. 2003
    ....
  44. ncbi Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection
    Melissa D Murphy
    Medical and Research Services, Portland VA Medical Center, Oregon 97201, USA
    Dig Dis Sci 47:1195-205. 2002
    ..However, the finding of greater variability among treatment responders in the carboxy end of NS5A suggests that the V3 region merits further investigation...
  45. ncbi Outcome and management of hepatitis C in liver transplant recipients
    Susan E Chan
    Division of Gastroenterology/Hepatology, Portland Veterans Affairs Medical Center, Portland, Oregon 97207, USA
    Clin Infect Dis 37:807-12. 2003
    ..As current antiviral therapy is limited in efficacy and tolerability, an improved understanding of those patients at greatest risk of developing serious HCV-induced graft injury is necessary to optimize treatment...
  46. ncbi Comparative analysis of outcome following liver transplantation in US veterans
    Gregory L Austin
    Department of Medicine, Division of Gastroenterology and Hepatology, Portland Veterans Affairs Medical Center and Oregon Health and Science University, Portland, OR, USA
    Am J Transplant 4:788-95. 2004
    ..219 (gender) + 0.018 (donor age) + 0.032 (recipient age) + 0.021 (MELD), where recipient age, donor age, and MELD score are the respective continuous variables and gender = 1 (men) and 0 for women (c-statistic = 0.71)...
  47. ncbi Immune evasion versus recovery after acute hepatitis C virus infection from a shared source
    Ian Tester
    Department of Medicine, Portland Veterans Administration Medical Center, Oregon Health Science University, Portland, OR 97239, USA
    J Exp Med 201:1725-31. 2005
    ..Statistical evidence for positive Darwinian selective pressure against an immunodominant epitope is presented. Wild-type cytotoxic T lymphocytes persisted even after the cognate antigen was no longer present...
  48. ncbi Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C
    Hugo R Rosen
    Division of Gastroenterology, Portland VAMC and Oregon Health Sciences University, 97207, USA
    Am J Gastroenterol 97:714-20. 2002
    ....
  49. ncbi Retransplantation for recurrent hepatitis C in the MELD era: maximizing utility
    James R Burton
    Division of Gastroenterology Hepatology, Oregon Health and Science University, Portland, OR, USA
    Liver Transpl 10:S59-64. 2004
    ..Utility starts to decline at MELD scores above 28. 5. The current allocation system (MELD) fails to maximize utility with regard to re-LT...
  50. ncbi Pretransplantation CD56(+) innate lymphocyte populations associated with severity of hepatitis C virus recurrence
    Hugo R Rosen
    Division of Gastroenterology and Hepatology, Liver Transplantation Program Hepatitis C Research Center, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Liver Transpl 14:31-40. 2008
    ....
  51. ncbi Immunosuppression impact on long-term cardiovascular complications after liver transplantation
    John M Rabkin
    Department of Surgery, Division of Abdominal Organ Transplantation, Oregon Health Sciences University, 3181 SW Sam Jackson Park Rd L590, Portland, Oregon 97201 3098, USA
    Am J Surg 183:595-9. 2002
    ..Cardiovascular disease and associated risk factors have been shown in renal transplant patients to be related to the pharmacologic immunosuppression employed...
  52. ncbi Novel CD4+ and CD8+ T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection
    Anne M Wertheimer
    Department of Medicine and Research Services, Portland Veterans Affairs Medical Center/Oregon Health and Science University, Portland, OR 97207, USA
    Hepatology 37:577-89. 2003
    ..By providing a comprehensive screening of all potential T-cell epitopes contained in the NS3 region, our strategy defines the breadth of the T-cell response and identifies novel, unpredicted specificities...
  53. ncbi Retransplantation for hepatic allograft failure: prognostic modeling and ethical considerations
    Scott W Biggins
    Department of Medicine, Portland Veterans Affairs Medical Center and Oregon Health Sciences University, Portland, OR 97207, USA
    Liver Transpl 8:313-22. 2002
    ..e., outcomes-based versus urgency-based approaches...
  54. ncbi Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction
    Lucy Golden-Mason
    Division of Gastroenterology Hepatology, Hepatitis C Center, University of Colorado Health Sciences Center and National Jewish Hospital, Denver, CO 80262, USA
    J Virol 81:9249-58. 2007
    ..Our data indicate that the PD-1/PD-L pathway is critical in persistent HCV infection in humans and represents a potential novel target for restoring function of exhausted HCV-specific CTLs...
  55. ncbi Spontaneous recovery in acute human hepatitis C virus infection: functional T-cell thresholds and relative importance of CD4 help
    Susan Smyk-Pearson
    GI and Hepatology Division, B 158, Academic Office Building 1, 12631 East 17th Ave, Room 7614, P O Box 6511, Aurora, CO 80045, USA
    J Virol 82:1827-37. 2008
    ..These results have important implications for early prediction of the virologic outcome following acute HCV and for the development of novel immunotherapeutic approaches...
  56. ncbi Engulfment of apoptotic cells expressing HCV proteins leads to differential chemokine expression and STAT signaling in human dendritic cells
    Anne M Wertheimer
    Department of Medicine, Portland VAMC and Oregon Health and Science University, Portland, OR, USA
    Hepatology 45:1422-32. 2007
    ..CONCLUSION: These data provide novel mechanisms by which HCV subverts antiviral host immunity...
  57. ncbi Basic concepts in transplant immunology
    Olivia M Martinez
    Stanford University School of Medicine, Stanford, CA 94305-5492, USA
    Liver Transpl 11:370-81. 2005
  58. ncbi Liver and intestine transplantation
    Robert S Brown
    Columbia University College of Physicians and Surgeons, New York, NY, USA
    Am J Transplant 4:81-92. 2004
    ..As this procedure matures, its application may increase to include recipients at an earlier stage of their disease with better likelihood of success...
  59. ncbi Direct enumeration and functional assessment of circulating dendritic cells in patients with liver disease
    Anne M Wertheimer
    Division of Gastroenterology/Hepatology, Oregon Health and Science University, Portland, OR 97239-2999, USA
    Hepatology 40:335-45. 2004
    ..Considering that DCs are essential for initiation and regulation of innate and adaptive immunity, these findings have implications for both viral persistence and liver disease...
  60. ncbi Identification of a hepatitis C virus-reactive T cell receptor that does not require CD8 for target cell recognition
    Glenda G Callender
    Department of Surgery, University of Chicago Hospitals, Chicago, IL, USA
    Hepatology 43:973-81. 2006
    ..These data suggest this high affinity HCV-specific TCR might have potential new immunotherapic implications...
  61. ncbi Treatment of hepatitis C in solid organ transplantation
    Susan E Chan
    Division of Gastroenterology and Hepatology, Oregon Health and Science University, Portland, Oregon, USAPortland Veterans Affairs Medical Center, Portland, Oregon 97201, USA
    Drugs 64:489-98. 2004
    ..Therefore, treatment using interferon and ribavirin is advocated; however, such therapy is frequently limited by adverse effects. Thus, improved antiviral treatment modalities are eagerly awaited in the transplant setting...
  62. ncbi Liver transplantation for hepatocellular carcinoma: a survey of practices
    Erik J Van Kleek
    Department of Internal Medicine, Oregon Health and Sciences University, Portland, OR 97239, USA
    J Clin Gastroenterol 40:643-7. 2006
    ..Variations of responses regarding biopsy of lesions, patient selection for deceased donor and living donor transplantation highlight a need for evidence-based guidelines...
  63. ncbi DNA vaccination protects mice against challenge with Listeria monocytogenes expressing the hepatitis C virus NS3 protein
    Benjamin E Simon
    Department of Veterans Affairs Medical Center, Portland, Oregon 97239, USA
    Infect Immun 71:6372-80. 2003
    ..These findings suggest that recombinant strains of L. monocytogenes expressing HCV antigens should prove useful for evaluating, or even inducing, protective immune responses against HCV antigens...
  64. ncbi A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection
    Ying Huang
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 104:985-90. 2007
    ....
  65. ncbi Assessment of FIBROSpect II to detect hepatic fibrosis in chronic hepatitis C patients
    Atif Zaman
    Division of Gastroenterology and Hepatology, Oregon Health and Science University, Portland, Oregon 97201, USA
    Am J Med 120:280.e9-14. 2007
    ..Our objective was to prospectively validate a panel of serum fibrosis markers (FIBROSpect(SM) II) that has been recently developed...
  66. ncbi An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection
    Roniel Cabrera
    Section of Hepatobiliary Diseases, Department of Medicine, University of Florida, Gainesville, FL 32610-0214, USA
    Hepatology 40:1062-71. 2004
    ..In conclusion, CD4(+)CD25(+) T lymphocytes constitute a highly differentiated population and appear to play a role in viral persistence by suppressing HCV-specific T cell responses in a cell-cell contact manner...